3-吗啉-5-(三氟甲基)苯甲酸 | 250682-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 3-吗啉-5-(三氟甲基)苯甲酸
• 英文名称: 3-(4-morpholin-4-yl)-5-trifluoromethylbenzoic acid
• 英文别名: 3-morpholino-5-(trifluoromethyl)benzoic acid；3-Morpholin-4-yl-5-trifluoromethyl-benzoic acid；3-morpholin-4-yl-5-(trifluoromethyl)benzoic acid
• CAS: 250682-08-7
• 化学式: C₁₂H₁₂F₃NO₃
• mdl: MFCD11845699
• 分子量: 275.227
• InChiKey: OWTBZZMSUFMFBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-吗啉-5-(三氟甲基)苯甲酸 在 palladium on activated charcoal 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 N-(2-((4-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)pyrimidin-2-yl)amino)ethyl)-3-morpholino-5-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies

  摘要：

  A series of imidazothiazole derivatives possessing potential activity against melanoma cells were investigated for molecular mechanism of action. The target compounds were tested against V600E-B-RAF and RAF1 kinases. Compound1zbis the most potent against both kinases with IC(50)values 0.978 and 8.2 nM, respectively. It showed relative selectivity against V600E mutant B-RAF kinase. Compound1zbwas also tested against four melanoma cell lines and exerted superior potency (IC(50)0.18-0.59 mu M) compared to the reference standard drug, sorafenib (IC(50)1.95-5.45 mu M). Compound1zbdemonstrated also prominent selectivity towards melanoma cells than normal skin cells. It was further tested in whole-cell kinase assay and showed in-cell V600E-B-RAF kinase inhibition with IC(50)of 0.19 mu M. Compound1zbinduces apoptosis not necrosis in the most sensitive melanoma cell line, UACC-62. Furthermore, molecular dynamic and 3D-QSAR studies were done to investigate the binding mode and understand the pharmacophoric features of this series of compounds.

  DOI：

  10.1080/14756366.2020.1819260
• 作为产物：
  描述：

  3-氟-5-(三氟甲基)苯甲腈 在 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 、 水 、 二甲基亚砜 为溶剂， 反应 60.0h， 生成 3-吗啉-5-(三氟甲基)苯甲酸
  参考文献：
  名称：

  WO2009/819

  摘要：

  公开号：

文献信息

• 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS
  申请人：Bissantz Caterina

  公开号：US20120232051A1

  公开（公告）日：2012-09-13

  This invention relates to novel 3-aminopyridines of the formula wherein B 1 , B 2 and R 1 to R 6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

  这项发明涉及以下结构的新型3-氨基吡啶： 其中B1、B2和R1至R6如描述和索赔中所定义，并且其药学上可接受的盐。这些化合物是GPBAR1激动剂，可用作治疗诸如2型糖尿病等疾病的药物。
• THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Industry-University Cooperation Foundation Hanyang University ERICA Campus

  公开号：US20180037589A1

  公开（公告）日：2018-02-08

  The present invention relates to novel thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same. The thienodiazepine derivatives or pharmaceutically acceptable salts thereof exhibit selective inhibition activities against protein kinases such as c-Kit, FLT3, FMS, LYN, RAF1, VEGFR3, PDGFRa, PDGFRb, RET, etc., and thus can be used as a pharmaceutical composition for prevention or treatment of abnormal cell growth diseases.

  本发明涉及新型噻二唑啉衍生物或其药用盐，以及包括它们的药物组合物。这些噻二唑啉衍生物或其药用盐对蛋白激酶如c-Kit、FLT3、FMS、LYN、RAF1、VEGFR3、PDGFRa、PDGFRb、RET等表现出选择性抑制活性，因此可用作预防或治疗异常细胞生长疾病的药物组合物。
• Benzamide derivatives and their use as cytokine inhibitors
  申请人：Astra Zeneca AB

  公开号：US06455520B1

  公开（公告）日：2002-09-24

  The invention concerns amide derivatives of formula (I) wherein R3 is (1-6C)alkyl or halogeno; m is 0-3, p is 0-2 and q is 0-4; each of R1 and R2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R4 is a basic group such as amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, di-[(1-6C)alkyl]amino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, heteroaryl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; and Q2 is a group such as heteroaryl, heteroaryloxy or heteroaryl-(1-6C)alkoxy which is optionally substituted; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  该发明涉及式(I)的酰胺衍生物 其中R3是(1-6C)烷基或卤素；m为0-3，p为0-2，q为0-4；R1和R2中的每一个是羟基、卤素、三氟甲基和氰基等基团；R4是氨基、(1-6C)烷基氨基、二-[（1-6C）烷基]氨基、二-[（1-6C）烷基]氨基-(1-6C)烷基、二-[（1-6C）烷基]氨基-(2-6C)氧烷基、杂环芳基、杂环芳氧基、杂环芳基-(1-6C)氧烷基、杂环烷基、杂环氧基和杂环烷基-(1-6C)氧烷基；Q2是杂环芳基、杂环芳氧基或杂环芳基-(1-6C)氧烷基等基团，可选择性地被取代；或其药学上可接受的盐或体内可水解酯；它们的制备方法、含有它们的药物组合物以及它们在治疗由细胞因子介导的疾病或医疗状况中的用途。
• Bezamide derivatives for the treatment of diseases mediated by cytokines
  申请人：AstraZeneca AB

  公开号：US06579872B1

  公开（公告）日：2003-06-17

  The invention concerns the use of amide derivatives of formula (I) wherein: R1 and R2 are substituents such as hydroxy, C1-6alkoxy, mercapto, C1-6alkylthio, amino, C1-6alkylamino and di-(C1-6alkyl)amino; m and p are independently 0-3; R3 is C1-4alkyl; q is 0-4; and R4 is aryl or cycloalkyl; or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及使用式（I）的酰胺衍生物，其中：R1和R2是取代基，例如羟基，C1-6烷氧基，巯基，C1-6烷基硫基，氨基，C1-6烷基氨基和二（C1-6烷基）氨基；m和p独立地为0-3；R3为C1-4烷基；q为0-4；而R4为芳基或环烷基；或其药学上可接受的盐制剂，用于制造治疗因细胞因子介导的疾病或医疗条件的药物。
• 1,3,6-SUBSTITUTED INDOLE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE
  申请人：Sim Tae Bo

  公开号：US20110046370A1

  公开（公告）日：2011-02-24

  Disclosed are a 1,3,6-substituted indole compound having inhibitory activity for protein kinases, a pharmaceutically acceptable thereof, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth including the compound as an active ingredient. Since the novel indole compound exhibits superior inhibitory activity for various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.

  揭示了一种具有蛋白激酶抑制活性的1,3,6-取代吲哚化合物，其药学上可接受，以及一种包含该化合物作为活性成分的用于预防和治疗由异常细胞生长引起的疾病的药物组合物。 由于这种新型吲哚化合物表现出对参与生长因子信号传导的各种蛋白激酶具有优越的抑制活性，因此它可用作预防或治疗由异常细胞生长引起的癌症的药物。